Interleukin-13
Latest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator Sanofi-Synthelabo
- Developer Nonindustrial source; Sanofi-Synthelabo
- Class Antirheumatics; Immunotherapies; Interleukins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Acute myeloid leukaemia; HIV-1 infections; Rheumatoid arthritis